The Role of Gut-oral Axis Microbiome in Autism Spectrum Disorders

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Autism Spectrum Disorder (ASD) is a neurodevelopment disorder characterized by impairment in social interaction, communication, and behavior, as well as sensory challenges. In addition, secondary symptoms can appear, such as gastrointestinal disorders. Gut microbiota has an important role in the harvest of nutrients and energy from our diet. It influences a wide range of metabolic, developmental, and physiological processes such as the maintenance of the gut epithelial layer, immune system development, protection against pathogens, detoxification and xenobiotics degradation. The ecosystem of a healthy human gastrointestinal (GI) tract is mainly populated by Firmicutes and Bacteroidetes phyla, to a lesser extent by Actinobacteria and Proteobacteria, in this case the microbiota is in an eubiosis condition. Whether a disturbance of the microbial ecosystem occurs, gut microbiota is in a dysbiosis condition and it could lead different metabolic disorders. The two-way communication between gut microbiota and central nervous system (CNS) affects stress response, pain perception, neurochemistry and several disorders. The gut microbiota in ASD patients revealed some peculiarities such as the high percentage of Propionibacter and Clostridium, well known for their production of pro inflammatory metabolites, or an increment of Sutterella spp. and Ruminococcus torques, which are negatively associated with the health of the gut. Recent studies suggest that also the oral microbiota may be involved in ASD symptoms assuming the existence of a microbiota-oral-brain axis. ASD patients are often suffering of several oral cavity disorders like caries, gingivitis and periodontitis, probably due to the poor oral hygiene. These disorders are linked to a dysbiosis of the oral microbiota: the characterization of the ASD subjects oral microbiota showed a lower biodiversity of bacteria species and different levels of specific bacteria, comparing to the controls. Several studies suggest that some bacteria species invade the blood-brain barriers as well as their metabolites, triggering inflammatory response and an alteration of the metabolic activity in the CNS. It has been demonstrated that ASD patients have a high level of pro-inflammatory cytokines and chemokines in the cerebrospinal fluid and an upregulation of the microglia. The oral microbiota could also affect the lower GI tract and have a significant role within the ASD-associated GI disorders and CNS inflammation

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 17
Healthy Volunteers: f
View:

⁃ Case group

• Caucasian

• Diagnosed with ASD or with a newly formulated diagnosis of ASD

• Aged between 1 and 17 years

⁃ Control group

• Caucasian

• Healthy at the time of sampling

• No ASD or other neurological disorders

• Aged between 1 and 17 years

Locations
Other Locations
Italy
Institute for Maternal and Child Health - IRCCS Burlo Garofolo
RECRUITING
Trieste
Contact Information
Primary
Manola Comar, BSc
manola.comar@burlo.trieste.it
+39.040.3785.527
Backup
Manola Comar, BSc
manola.comar@burlo.trieste.it
+390403785527
Time Frame
Start Date: 2021-05-20
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 86
Treatments
Children with autism disorders 1-5 years
Children coming to the Division of Child Neurology and Psychiatry for the first clinical evaluation (1 year to 5 years old)
Children with autism disorders 6-17 years
Children with confirmed ASD diagnosis (6 years to 17 years old) coming to the Odonto-Stomatology Department for the periodical dental hygiene session
Children control group
Children with matched demographic characteristics accessing our Institute for different purposes
Related Therapeutic Areas
Sponsors
Leads: IRCCS Burlo Garofolo

This content was sourced from clinicaltrials.gov